middle.news
Paradigm Secures $5.75 Million in Government R&D Refunds to Bolster Phase 3 Osteoarthritis Push
8:18am on Wednesday 22nd of July, 2026 AEST
•
Healthcare
Read Story
Paradigm Secures $5.75 Million in Government R&D Refunds to Bolster Phase 3 Osteoarthritis Push
8:18am on Wednesday 22nd of July, 2026 AEST
Key Points
Received $4.82 million R&D tax refund for FY25
Additional $0.93 million refund from amended FY23 tax assessment
Funds to support Phase 3 iPPS clinical program and NDA activities
Strengthened financial position amid ongoing trial milestones
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE